A monthly pharma newsletter from consultancy Galenisys mixing first-person war stories from GMP auditing and quality work with short pieces on industry trends such as GLP-1 drugs and orexins. Readers get practical quality, contamination control and project management lessons alongside light market commentary.

Chivanta is a weekly Chinese-language newsletter by a former biotech industry professional who analyses the business side of life sciences, including business development, licensing, CDMO operations and market strategy. Recent issues mix practical lessons from industry work, such as backing research from market needs and estimating GMP manufacturing timelines and costs, with personal reflections.

A daily-style biopharma newsletter offering commentary on therapeutics, regulatory oversight and clinical trials, organised around weekday themes. Readers get a short, opinionated take on industry developments such as biosimilar choices, regulator priorities and upcoming conference data.

Jean-Claude Muller, a former Sanofi SVP, offers strategic commentary on biomedical innovation, R&D strategy and biotech markets, including a review of French biotech companies' recent performance. His French-language posts also give personal, opinion-led takes on social inequality and the 2027 French presidential election.